3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Pancreatic Neoplasms
74
Carcinoma, Non-Small-Cell Lung
73
Breast Neoplasms
39
Lung Neoplasms
31
Urinary Bladder Neoplasms
28
Nasopharyngeal Carcinoma
28
Ovarian Neoplasms
25
Neoplasm Metastasis
21
Cholangiocarcinoma
18
Triple Negative Breast Neoplasms
16
Neoplasms
16
Lymphoma, Large B-Cell, Diffuse
13
Gallbladder Neoplasms
13
Biliary Tract Neoplasms
13
Uterine Cervical Neoplasms
12
Recurrence
12
Carcinoma, Transitional Cell
12
Nasopharyngeal Neoplasms
11
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Fallopian Tube Neoplasms
10
Non-Muscle Invasive Bladder Neoplasms
9
Lymphoma
7
Carcinoma
7
Bile Duct Neoplasms
7
Lymphoma, Non-Hodgkin
6
Adenocarcinoma
6
Carcinoma, Hepatocellular
5
Adenocarcinoma of Lung
5
Neoplasms by Site
4
Urothelial Cancer
3
Interventions
Mitomycin
2
valrubicin
1
pembrolizumab
1
enfortumab vedotin
1
Standard of Care
1
Radiation Dose Hypofractionation
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Urologic Diseases
×
Gemcitabine
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled